Global Nano Antibodies Market 2024 by Company, Regions, Type and Application, Forecast to 2030
1 Market Overview
- 1.1 Product Overview and Scope of Nano Antibodies
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Classification of Nano Antibodies by Type
- 1.3.1 Overview: Global Nano Antibodies Market Size by Type: 2019 Versus 2023 Versus 2030
- 1.3.2 Global Nano Antibodies Consumption Value Market Share by Type in 2023
- 1.3.3 Monovalent Nanobody
- 1.3.4 Multivalent and multispecific Nanobodies
- 1.3.5 Fusion Nanobody
- 1.4 Global Nano Antibodies Market by Application
- 1.4.1 Overview: Global Nano Antibodies Market Size by Application: 2019 Versus 2023 Versus 2030
- 1.4.2 Disease detection in vitro
- 1.4.3 Non-invasive diagnosis in vivo
- 1.4.4 Tumor targeted therapy
- 1.4.5 Nervous system disease
- 1.4.6 Circulatory disease
- 1.4.7 Infectious disease
- 1.4.8 Other
- 1.5 Global Nano Antibodies Market Size & Forecast
- 1.6 Global Nano Antibodies Market Size and Forecast by Region
- 1.6.1 Global Nano Antibodies Market Size by Region: 2019 VS 2023 VS 2030
- 1.6.2 Global Nano Antibodies Market Size by Region, (2019-2030)
- 1.6.3 North America Nano Antibodies Market Size and Prospect (2019-2030)
- 1.6.4 Europe Nano Antibodies Market Size and Prospect (2019-2030)
- 1.6.5 Asia-Pacific Nano Antibodies Market Size and Prospect (2019-2030)
- 1.6.6 South America Nano Antibodies Market Size and Prospect (2019-2030)
- 1.6.7 Middle East and Africa Nano Antibodies Market Size and Prospect (2019-2030)
2 Company Profiles
- 2.1 Merck KGaA
- 2.1.1 Merck KGaA Details
- 2.1.2 Merck KGaA Major Business
- 2.1.3 Merck KGaA Nano Antibodies Product and Solutions
- 2.1.4 Merck KGaA Nano Antibodies Revenue, Gross Margin and Market Share (2019-2024)
- 2.1.5 Merck KGaA Recent Developments and Future Plans
- 2.2 Sanofi (Ablynx)
- 2.2.1 Sanofi (Ablynx) Details
- 2.2.2 Sanofi (Ablynx) Major Business
- 2.2.3 Sanofi (Ablynx) Nano Antibodies Product and Solutions
- 2.2.4 Sanofi (Ablynx) Nano Antibodies Revenue, Gross Margin and Market Share (2019-2024)
- 2.2.5 Sanofi (Ablynx) Recent Developments and Future Plans
- 2.3 Alphamab Oncology
- 2.3.1 Alphamab Oncology Details
- 2.3.2 Alphamab Oncology Major Business
- 2.3.3 Alphamab Oncology Nano Antibodies Product and Solutions
- 2.3.4 Alphamab Oncology Nano Antibodies Revenue, Gross Margin and Market Share (2019-2024)
- 2.3.5 Alphamab Oncology Recent Developments and Future Plans
- 2.4 Novartis AG
- 2.4.1 Novartis AG Details
- 2.4.2 Novartis AG Major Business
- 2.4.3 Novartis AG Nano Antibodies Product and Solutions
- 2.4.4 Novartis AG Nano Antibodies Revenue, Gross Margin and Market Share (2019-2024)
- 2.4.5 Novartis AG Recent Developments and Future Plans
- 2.5 Genscript
- 2.5.1 Genscript Details
- 2.5.2 Genscript Major Business
- 2.5.3 Genscript Nano Antibodies Product and Solutions
- 2.5.4 Genscript Nano Antibodies Revenue, Gross Margin and Market Share (2019-2024)
- 2.5.5 Genscript Recent Developments and Future Plans
- 2.6 Taisho Pharmaceutical Holdings
- 2.6.1 Taisho Pharmaceutical Holdings Details
- 2.6.2 Taisho Pharmaceutical Holdings Major Business
- 2.6.3 Taisho Pharmaceutical Holdings Nano Antibodies Product and Solutions
- 2.6.4 Taisho Pharmaceutical Holdings Nano Antibodies Revenue, Gross Margin and Market Share (2019-2024)
- 2.6.5 Taisho Pharmaceutical Holdings Recent Developments and Future Plans
- 2.7 Sensei Biotherapeutics, Inc.
- 2.7.1 Sensei Biotherapeutics, Inc. Details
- 2.7.2 Sensei Biotherapeutics, Inc. Major Business
- 2.7.3 Sensei Biotherapeutics, Inc. Nano Antibodies Product and Solutions
- 2.7.4 Sensei Biotherapeutics, Inc. Nano Antibodies Revenue, Gross Margin and Market Share (2019-2024)
- 2.7.5 Sensei Biotherapeutics, Inc. Recent Developments and Future Plans
- 2.8 Cusabio Technology LLC.
- 2.8.1 Cusabio Technology LLC. Details
- 2.8.2 Cusabio Technology LLC. Major Business
- 2.8.3 Cusabio Technology LLC. Nano Antibodies Product and Solutions
- 2.8.4 Cusabio Technology LLC. Nano Antibodies Revenue, Gross Margin and Market Share (2019-2024)
- 2.8.5 Cusabio Technology LLC. Recent Developments and Future Plans
- 2.9 ChromoTek GmbH
- 2.9.1 ChromoTek GmbH Details
- 2.9.2 ChromoTek GmbH Major Business
- 2.9.3 ChromoTek GmbH Nano Antibodies Product and Solutions
- 2.9.4 ChromoTek GmbH Nano Antibodies Revenue, Gross Margin and Market Share (2019-2024)
- 2.9.5 ChromoTek GmbH Recent Developments and Future Plans
- 2.10 Beroni Group
- 2.10.1 Beroni Group Details
- 2.10.2 Beroni Group Major Business
- 2.10.3 Beroni Group Nano Antibodies Product and Solutions
- 2.10.4 Beroni Group Nano Antibodies Revenue, Gross Margin and Market Share (2019-2024)
- 2.10.5 Beroni Group Recent Developments and Future Plans
- 2.11 ExeVir Bio BV
- 2.11.1 ExeVir Bio BV Details
- 2.11.2 ExeVir Bio BV Major Business
- 2.11.3 ExeVir Bio BV Nano Antibodies Product and Solutions
- 2.11.4 ExeVir Bio BV Nano Antibodies Revenue, Gross Margin and Market Share (2019-2024)
- 2.11.5 ExeVir Bio BV Recent Developments and Future Plans
- 2.12 Absolute Antibody
- 2.12.1 Absolute Antibody Details
- 2.12.2 Absolute Antibody Major Business
- 2.12.3 Absolute Antibody Nano Antibodies Product and Solutions
- 2.12.4 Absolute Antibody Nano Antibodies Revenue, Gross Margin and Market Share (2019-2024)
- 2.12.5 Absolute Antibody Recent Developments and Future Plans
- 2.13 Alpalife (Shenzhen kangti Co., Ltd.)
- 2.13.1 Alpalife (Shenzhen kangti Co., Ltd.) Details
- 2.13.2 Alpalife (Shenzhen kangti Co., Ltd.) Major Business
- 2.13.3 Alpalife (Shenzhen kangti Co., Ltd.) Nano Antibodies Product and Solutions
- 2.13.4 Alpalife (Shenzhen kangti Co., Ltd.) Nano Antibodies Revenue, Gross Margin and Market Share (2019-2024)
- 2.13.5 Alpalife (Shenzhen kangti Co., Ltd.) Recent Developments and Future Plans
- 2.14 DiosCURE Therapeutics SE
- 2.14.1 DiosCURE Therapeutics SE Details
- 2.14.2 DiosCURE Therapeutics SE Major Business
- 2.14.3 DiosCURE Therapeutics SE Nano Antibodies Product and Solutions
- 2.14.4 DiosCURE Therapeutics SE Nano Antibodies Revenue, Gross Margin and Market Share (2019-2024)
- 2.14.5 DiosCURE Therapeutics SE Recent Developments and Future Plans
- 2.15 Thermo Fisher Scientific Inc.
- 2.15.1 Thermo Fisher Scientific Inc. Details
- 2.15.2 Thermo Fisher Scientific Inc. Major Business
- 2.15.3 Thermo Fisher Scientific Inc. Nano Antibodies Product and Solutions
- 2.15.4 Thermo Fisher Scientific Inc. Nano Antibodies Revenue, Gross Margin and Market Share (2019-2024)
- 2.15.5 Thermo Fisher Scientific Inc. Recent Developments and Future Plans
- 2.16 PerkinElmer Inc. (BioLegend, Inc.)
- 2.16.1 PerkinElmer Inc. (BioLegend, Inc.) Details
- 2.16.2 PerkinElmer Inc. (BioLegend, Inc.) Major Business
- 2.16.3 PerkinElmer Inc. (BioLegend, Inc.) Nano Antibodies Product and Solutions
- 2.16.4 PerkinElmer Inc. (BioLegend, Inc.) Nano Antibodies Revenue, Gross Margin and Market Share (2019-2024)
- 2.16.5 PerkinElmer Inc. (BioLegend, Inc.) Recent Developments and Future Plans
3 Market Competition, by Players
- 3.1 Global Nano Antibodies Revenue and Share by Players (2019-2024)
- 3.2 Market Share Analysis (2023)
- 3.2.1 Market Share of Nano Antibodies by Company Revenue
- 3.2.2 Top 3 Nano Antibodies Players Market Share in 2023
- 3.2.3 Top 6 Nano Antibodies Players Market Share in 2023
- 3.3 Nano Antibodies Market: Overall Company Footprint Analysis
- 3.3.1 Nano Antibodies Market: Region Footprint
- 3.3.2 Nano Antibodies Market: Company Product Type Footprint
- 3.3.3 Nano Antibodies Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
- 4.1 Global Nano Antibodies Consumption Value and Market Share by Type (2019-2024)
- 4.2 Global Nano Antibodies Market Forecast by Type (2025-2030)
5 Market Size Segment by Application
- 5.1 Global Nano Antibodies Consumption Value Market Share by Application (2019-2024)
- 5.2 Global Nano Antibodies Market Forecast by Application (2025-2030)
6 North America
- 6.1 North America Nano Antibodies Consumption Value by Type (2019-2030)
- 6.2 North America Nano Antibodies Consumption Value by Application (2019-2030)
- 6.3 North America Nano Antibodies Market Size by Country
- 6.3.1 North America Nano Antibodies Consumption Value by Country (2019-2030)
- 6.3.2 United States Nano Antibodies Market Size and Forecast (2019-2030)
- 6.3.3 Canada Nano Antibodies Market Size and Forecast (2019-2030)
- 6.3.4 Mexico Nano Antibodies Market Size and Forecast (2019-2030)
7 Europe
- 7.1 Europe Nano Antibodies Consumption Value by Type (2019-2030)
- 7.2 Europe Nano Antibodies Consumption Value by Application (2019-2030)
- 7.3 Europe Nano Antibodies Market Size by Country
- 7.3.1 Europe Nano Antibodies Consumption Value by Country (2019-2030)
- 7.3.2 Germany Nano Antibodies Market Size and Forecast (2019-2030)
- 7.3.3 France Nano Antibodies Market Size and Forecast (2019-2030)
- 7.3.4 United Kingdom Nano Antibodies Market Size and Forecast (2019-2030)
- 7.3.5 Russia Nano Antibodies Market Size and Forecast (2019-2030)
- 7.3.6 Italy Nano Antibodies Market Size and Forecast (2019-2030)
8 Asia-Pacific
- 8.1 Asia-Pacific Nano Antibodies Consumption Value by Type (2019-2030)
- 8.2 Asia-Pacific Nano Antibodies Consumption Value by Application (2019-2030)
- 8.3 Asia-Pacific Nano Antibodies Market Size by Region
- 8.3.1 Asia-Pacific Nano Antibodies Consumption Value by Region (2019-2030)
- 8.3.2 China Nano Antibodies Market Size and Forecast (2019-2030)
- 8.3.3 Japan Nano Antibodies Market Size and Forecast (2019-2030)
- 8.3.4 South Korea Nano Antibodies Market Size and Forecast (2019-2030)
- 8.3.5 India Nano Antibodies Market Size and Forecast (2019-2030)
- 8.3.6 Southeast Asia Nano Antibodies Market Size and Forecast (2019-2030)
- 8.3.7 Australia Nano Antibodies Market Size and Forecast (2019-2030)
9 South America
- 9.1 South America Nano Antibodies Consumption Value by Type (2019-2030)
- 9.2 South America Nano Antibodies Consumption Value by Application (2019-2030)
- 9.3 South America Nano Antibodies Market Size by Country
- 9.3.1 South America Nano Antibodies Consumption Value by Country (2019-2030)
- 9.3.2 Brazil Nano Antibodies Market Size and Forecast (2019-2030)
- 9.3.3 Argentina Nano Antibodies Market Size and Forecast (2019-2030)
10 Middle East & Africa
- 10.1 Middle East & Africa Nano Antibodies Consumption Value by Type (2019-2030)
- 10.2 Middle East & Africa Nano Antibodies Consumption Value by Application (2019-2030)
- 10.3 Middle East & Africa Nano Antibodies Market Size by Country
- 10.3.1 Middle East & Africa Nano Antibodies Consumption Value by Country (2019-2030)
- 10.3.2 Turkey Nano Antibodies Market Size and Forecast (2019-2030)
- 10.3.3 Saudi Arabia Nano Antibodies Market Size and Forecast (2019-2030)
- 10.3.4 UAE Nano Antibodies Market Size and Forecast (2019-2030)
11 Market Dynamics
- 11.1 Nano Antibodies Market Drivers
- 11.2 Nano Antibodies Market Restraints
- 11.3 Nano Antibodies Trends Analysis
- 11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry
12 Industry Chain Analysis
- 12.1 Nano Antibodies Industry Chain
- 12.2 Nano Antibodies Upstream Analysis
- 12.3 Nano Antibodies Midstream Analysis
- 12.4 Nano Antibodies Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
- 14.1 Methodology
- 14.2 Research Process and Data Source
According to our (Global Info Research) latest study, the global Nano Antibodies market size was valued at USD 293.9 million in 2023 and is forecast to a readjusted size of USD 1345 million by 2030 with a CAGR of 24.3% during review period.
Nanoantibodies or "nAb" are single-domain VHH antibodies derived from camelidae (camels, llamas, alpacas, etc.). Compared with conventional monoclonal and polyclonal antibodies, nAbs have the following advantages:
Small size (~15kd)
High affinity (frequently nanomolar range)
High specificity
Unsurpassed stability
纳米抗体在研究、诊断和治疗用途中越来越受欢迎。然而,高生产成本和生产限制可能会阻碍全球纳米抗体市场的增长。
The Global Info Research report includes an overview of the development of the Nano Antibodies industry chain, the market status of Disease detection in vitro (Monovalent Nanobody, Multivalent and multispecific Nanobodies), Non-invasive diagnosis in vivo (Monovalent Nanobody, Multivalent and multispecific Nanobodies), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Nano Antibodies.
Regionally, the report analyzes the Nano Antibodies markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Nano Antibodies market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Nano Antibodies market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Nano Antibodies industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Monovalent Nanobody, Multivalent and multispecific Nanobodies).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Nano Antibodies market.
Regional Analysis: The report involves examining the Nano Antibodies market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Nano Antibodies market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Nano Antibodies:
Company Analysis: Report covers individual Nano Antibodies players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Nano Antibodies This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Disease detection in vitro, Non-invasive diagnosis in vivo).
Technology Analysis: Report covers specific technologies relevant to Nano Antibodies. It assesses the current state, advancements, and potential future developments in Nano Antibodies areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Nano Antibodies market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Nano Antibodies market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Monovalent Nanobody
Multivalent and multispecific Nanobodies
Fusion Nanobody
Market segment by Application
Disease detection in vitro
Non-invasive diagnosis in vivo
Tumor targeted therapy
Nervous system disease
Circulatory disease
Infectious disease
Other
Market segment by players, this report covers
Merck KGaA
Sanofi (Ablynx)
Alphamab Oncology
Novartis AG
Genscript
Taisho Pharmaceutical Holdings
Sensei Biotherapeutics, Inc.
Cusabio Technology LLC.
ChromoTek GmbH
Beroni Group
ExeVir Bio BV
Absolute Antibody
Alpalife (Shenzhen kangti Co., Ltd.)
DiosCURE Therapeutics SE
Thermo Fisher Scientific Inc.
PerkinElmer Inc. (BioLegend, Inc.)
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Nano Antibodies product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Nano Antibodies, with revenue, gross margin and global market share of Nano Antibodies from 2019 to 2024.
Chapter 3, the Nano Antibodies competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Nano Antibodies market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Nano Antibodies.
Chapter 13, to describe Nano Antibodies research findings and conclusion.